SNPnotes: high-throughput tissue-specific functional annotation of single nucleotide variants

Shraddha Pai,Michael J. Apostolides,Andrew Jung,Matthew A. Moss
DOI: https://doi.org/10.12688/f1000research.20415.1
2019-10-22
F1000Research
Abstract:A key challenge in the application of whole-genome sequencing (WGS) for clinical diagnostic and research is the high-throughput prioritization of functional variants in the non-coding genome. This challenge is compounded by context-specific genetic modulation of gene expression, and variant-gene mapping depends on the tissues and organ systems affected in a given disease; for instance, a disease affecting the gastrointestinal system would use maps specific to genome regulation in gut-related tissues. While there are large-scale atlases of genome regulation, such as GTEx and NIH Roadmap Epigenomics, the clinical genetics community lacks publicly-available stand-alone software for high-throughput annotation of custom variant data with user-defined tissue-specific epigenetic maps and clinical genetic databases, to prioritize variants for a specific biomedical application. In this work, we provide a simple software pipeline, called SNPnotes, which takes as input variant calls for a patient and prioritizes those using information on clinical relevance from ClinVar, tissue-specific gene regulation from GTEx and disease associations from the NHGRI-EBI GWAS catalogue. This pipeline was developed as part of SVAI Research's "Undiagnosed-1" event for collaborative patient diagnosis. We applied this pipeline to WGS-based variant calls for an individual with a history of gastrointestinal symptoms, using 12 gut-specific eQTL maps and GWAS associations for metabolic diseases, for variant-gene mapping. Out of 6,248,584 SNPs, the pipeline identified 151 high-priority variants, overlapping 129 genes. These top SNPs all have known clinical pathogenicity, modulate gene expression in gut tissues and have genetic associations with metabolic disorders, and serve as starting points for hypotheses about mechanisms driving clinical symptoms. Simple software changes can be made to customize the pipeline for other tissue-specific applications. Future extensions could integrate maps of tissue-specific regulatory elements, higher-order chromatin loops, and mutations affecting splice variants.
What problem does this paper attempt to address?